Ligand Pharmaceuticals Aktie

Ligand Pharmaceuticals für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN DE: A1C9RN / ISIN: US53220K5048

<
Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch
>
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>
07.11.2022 23:08:30

Ligand Pharmaceuticals Inc Q3 Profit Decreases, but beats estimates

(RTTNews) - Ligand Pharmaceuticals Inc (LGND) announced earnings for third quarter that decreased from last year but beat the Street estimates.

The company's bottom line came in at $0.40 million, or $0.02 per share. This compares with $13.72 million, or $0.80 per share, in last year's third quarter.

Excluding items, Ligand Pharmaceuticals Inc reported adjusted earnings of $22.49 million or $1.31 per share for the period.

Analysts on average had expected the company to earn $0.43 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.

The company's revenue for the quarter rose 1.9% to $66.09 million from $64.84 million last year.

Ligand Pharmaceuticals Inc earnings at a glance (GAAP) :

-Earnings (Q3): $0.40 Mln. vs. $13.72 Mln. last year. -EPS (Q3): $0.02 vs. $0.80 last year. -Analyst Estimates: $0.43 -Revenue (Q3): $66.09 Mln vs. $64.84 Mln last year.

-Guidance: Full year revenue guidance: $184 - $189 Mln

Analysen zu Ligand Pharmaceuticals Incmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Ligand Pharmaceuticals Inc 95,50 -4,02% Ligand Pharmaceuticals Inc